Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

NCT01686165 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Large Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions

DRUG: belinostat
BIOLOGICAL: rituximab
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

University of Arizona

Collaborators

[object Object]